Differences in baseline characteristics of newly diagnosed IPF patents in the EMPIRE countries
V. Müller (Budapest, Hungary), M. Šterclová (Prague, Czech Republic), N. Mogulkoc (Izmir, Turkey), J. Kus (Warsaw, Poland), M. Hájková (Bratislava, Slovakia), D. Jovanovic (Belgrade, Republic of Serbia), J. Tekavec-Trkanjec (Zagreb, Croatia), M. Svoboda (Brno, Czech Republic), M. Janotová (Brno, Czech Republic), M. Vašáková (Prague, Czech Republic)
Source: International Congress 2018 – The world of idiopathic pulmonary fibrosis (IPF): global registries
Disease area: Interstitial lung diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
V. Müller (Budapest, Hungary), M. Šterclová (Prague, Czech Republic), N. Mogulkoc (Izmir, Turkey), J. Kus (Warsaw, Poland), M. Hájková (Bratislava, Slovakia), D. Jovanovic (Belgrade, Republic of Serbia), J. Tekavec-Trkanjec (Zagreb, Croatia), M. Svoboda (Brno, Czech Republic), M. Janotová (Brno, Czech Republic), M. Vašáková (Prague, Czech Republic). Differences in baseline characteristics of newly diagnosed IPF patents in the EMPIRE countries. 2204
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: